HarrowHROW
HROW
About: Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Employees: 382
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
27% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 30
4% more funds holding
Funds holding: 158 [Q3] → 165 (+7) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 52
0.44% less ownership
Funds ownership: 58.91% [Q3] → 58.47% (-0.44%) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
26% less capital invested
Capital invested by funds: $940M [Q3] → $699M (-$241M) [Q4]
42% less call options, than puts
Call options by funds: $28.1M | Put options by funds: $48.7M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$57
146%
upside
Avg. target
$61
163%
upside
High target
$65
181%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Mayank Mamtani 9% 1-year accuracy 2 / 22 met price target | 181%upside $65 | Buy Maintained | 1 Apr 2025 |
HC Wainwright & Co. Yi Chen 29% 1-year accuracy 50 / 172 met price target | 146%upside $57 | Buy Reiterated | 31 Mar 2025 |
Financial journalist opinion
Based on 8 articles about HROW published over the past 30 days
Neutral
Business Wire
1 week ago
Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE® Access for All (“VAFA”) program to include patients currently prescribed Klarity-C Drops®, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx®, Harrow's compounding subsidiary. Since its launch on March 17, 2025, VEVYE Access for All has simplified dry eye therapy for eligible patients by eliminating access b.
Neutral
Seeking Alpha
3 weeks ago
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)
Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex reimbursement challenges and tough competition. Valuation models suggest Harrow is fairly valued if it achieves 20% revenue growth and 15% FCF margins, though these are lofty expectations.
Neutral
Seeking Alpha
3 weeks ago
Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call
Harrow, Inc. (NASDAQ:HROW ) Q4 2024 - Earnings Conference Call March 28, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Thomas Flaten - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann and Company Mayank Mamtani - B. Riley Securities Yi Chen - H.
Positive
Seeking Alpha
3 weeks ago
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp
Harrow, Inc. is a speculative buy, with potential trading gains from the $20s to the $30s, and long-term growth prospects. The company reported strong Q4 growth, with an 84% revenue increase and improved gross profit margins, driven by key products IHEEZO and VEVYE. Harrow's 2025 revenue guidance is bullish, expecting over $280 million, a 40% increase, supported by the VEVYE Access for All program.
Positive
Zacks Investment Research
3 weeks ago
Harrow (HROW) Q4 Earnings and Revenues Top Estimates
Harrow (HROW) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to loss of $0.27 per share a year ago.
Neutral
Business Wire
3 weeks ago
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2024. The Company also posted its fourth quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future.
Neutral
Business Wire
3 weeks ago
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its fourth quarter and audited financial results for the year ended December 31, 2024, on Thursday, March 27, 2025, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors” section of its website, harrow.com. Harrow will host a conference call and live webcast at 8:00 a.m. Eastern Time on Fri.
Neutral
Business Wire
4 weeks ago
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Harrow's transitional pass-through application for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocula.
Neutral
Business Wire
1 month ago
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced unaudited preliminary financial results for the fourth quarter and year ended December 31, 2024, as well as revenue guidance for 2025. Although Harrow was initially scheduled to release its audited financial results today, the Company's new independent auditor requires additional time to audit Harrow's financial presentation. As a result, Harrow is delaying its earn.
Neutral
Business Wire
1 month ago
Harrow Launches VEVYE® Access for All
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today introduced VEVYE® Access for All, a groundbreaking initiative that underscores Harrow's long‑standing commitment to access and affordability. This program, which is now available through our PhilRx specialty pharmacy partner, guarantees access to VEVYE (cyclosporine ophthalmic solution) 0.1% for eligible patients and health plans for $59, ensuring that every patient can affor.
Charts implemented using Lightweight Charts™